Activity Description & Educational Objectives
How should the practicing hematology-oncology professional approach the management of rare disorders such as myelofibrosis (MF)? This is an important question, particularly as recent years have seen clinically relevant updates on diagnosis, prognosis, and treatment in a historically moribund therapeutic context. In this three-part review, Dr. Jamile Shammo offers her clinical insights on the science that has changed the management of MF while also discussing several patient cases that illustrate how new tools and evidence can be used to improve care for patients suffering from this disease.
Upon completion of this activity, participants should be better able to:
- Recognize the signs and symptoms of myelofibrosis (MF), and distinguish this disease from other myeloproliferative neoplasms (MPNs)
- Develop and/or apply appropriate diagnostic and prognostic models for patients with MF
- Discuss the therapeutic role of JAK-STAT pathway inhibition in MF
- Select appropriate targeted or conventional therapy for a patient with MF based on baseline symptoms, symptom severity, and risk status
- Identify and implement recommended dosing and monitoring strategies for patients with MF eligible for targeted therapy
- Follow and appropriately manage a patient who is receiving therapy for MF
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, hematologists, and other health care professionals active or interested in the management of myelofibrosis.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Release and Expiration Dates: January 10, 2013 - January 09, 2014
Time to Complete: 45 minutes
Faculty & Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Course Director and Interviewee
Jamile M. Shammo, MD, FASCP, FACP
Associate Professor of Medicine and Pathology
Rush University Medical Center
Jamile M. Shammo, MD, FASCP, FACP, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Amgen Inc.; Celgene Corporation; and Incyte Corporation.
PVI, PeerView Institute for Medical Education
Carmine DeLuca currently has no financial interests/relationships or affiliations in relation to this activity.
Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Penn State College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5246-13-T.
This CME activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.